NO943521L - Anvendelse av et pyrrolidinacetamidderivat for fremstilling av et terapeutikum - Google Patents

Anvendelse av et pyrrolidinacetamidderivat for fremstilling av et terapeutikum

Info

Publication number
NO943521L
NO943521L NO943521A NO943521A NO943521L NO 943521 L NO943521 L NO 943521L NO 943521 A NO943521 A NO 943521A NO 943521 A NO943521 A NO 943521A NO 943521 L NO943521 L NO 943521L
Authority
NO
Norway
Prior art keywords
preparation
therapeutic agent
acetamide derivative
pyrrolidine acetamide
pyrrolidine
Prior art date
Application number
NO943521A
Other languages
English (en)
Norwegian (no)
Other versions
NO943521D0 (no
Inventor
Ernst Wulfert
Jean Gobert
Alma Gower
Eric Cossement
Original Assignee
Ucb Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Sa filed Critical Ucb Sa
Publication of NO943521D0 publication Critical patent/NO943521D0/no
Publication of NO943521L publication Critical patent/NO943521L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
NO943521A 1993-09-24 1994-09-22 Anvendelse av et pyrrolidinacetamidderivat for fremstilling av et terapeutikum NO943521L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939319732A GB9319732D0 (en) 1993-09-24 1993-09-24 Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety

Publications (2)

Publication Number Publication Date
NO943521D0 NO943521D0 (no) 1994-09-22
NO943521L true NO943521L (no) 1995-03-27

Family

ID=10742476

Family Applications (1)

Application Number Title Priority Date Filing Date
NO943521A NO943521L (no) 1993-09-24 1994-09-22 Anvendelse av et pyrrolidinacetamidderivat for fremstilling av et terapeutikum

Country Status (17)

Country Link
US (1) US5447952A (fi)
EP (1) EP0645139B1 (fi)
JP (1) JP3688735B2 (fi)
KR (1) KR950007848A (fi)
AT (1) ATE191849T1 (fi)
AU (1) AU672334B2 (fi)
CA (1) CA2132509A1 (fi)
DE (1) DE69424009T2 (fi)
ES (1) ES2145818T3 (fi)
GB (1) GB9319732D0 (fi)
HU (1) HU217124B (fi)
NO (1) NO943521L (fi)
NZ (1) NZ264506A (fi)
RU (1) RU2142274C1 (fi)
SG (1) SG86284A1 (fi)
TW (1) TW283642B (fi)
ZA (1) ZA947444B (fi)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525347A (en) * 1995-01-31 1996-06-11 Medical University Of South Carolina Composition and methods for treating performance anxiety
ATE361751T1 (de) 1999-12-01 2007-06-15 Ucb Sa Ein pyrrolidinacetatderivat zur behandlung von chronischem oder neuropathischem schmerz
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
JP2009524658A (ja) * 2006-01-24 2009-07-02 テバ ファーマシューティカル インダストリーズ リミティド レベチラセタム製剤、及びそれらの製造方法
US20090082394A1 (en) * 2006-03-15 2009-03-26 Actelion Pharmaceuticals, Ltd. Tetrahydroisoquinoline Derivatives to Enhance Memory Function
WO2008021666A2 (en) * 2006-08-18 2008-02-21 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
CA2691373A1 (en) * 2007-07-03 2009-01-08 Actelion Pharmaceuticals Ltd 3-aza-bicyclo[3.3.0]octane compounds
JP2010534647A (ja) * 2007-07-27 2010-11-11 アクテリオン ファーマシューティカルズ リミテッド ２−アザ−ビシクロ［３．３．０］オクタン誘導体
CN102227217A (zh) 2008-10-16 2011-10-26 约翰斯.霍普金斯大学 改善认知功能的方法和组合物
US8191547B2 (en) * 2008-10-23 2012-06-05 S-2Tech Llc Portable solar-heating system having an inflatable solar collector
US20100172979A1 (en) * 2008-12-24 2010-07-08 Zhongshui Yu Controlled-release formulations
US20100159009A1 (en) * 2008-12-24 2010-06-24 Zhongshui Yu Controlled-release formulations
EP2533645B1 (en) * 2010-02-09 2016-07-27 The Johns Hopkins University Methods and compositions for improving cognitive function
US20120214859A1 (en) * 2011-02-09 2012-08-23 Michela Gallagher Methods and compositions for improving cognitive function
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA
DK2968220T3 (da) 2013-03-15 2021-06-14 Agenebio Inc Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion
EP2968237A4 (en) 2013-03-15 2016-08-31 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
BR112017025031B1 (pt) 2015-05-22 2023-03-21 Agenebio, Inc Composições farmacêuticas de liberação prolongada de levetiracetam
US20220047548A1 (en) * 2018-12-04 2022-02-17 Metys Pharmaceuticals AG SYNERGISTIC COMPOSITIONS COMPRISING (R)-2-(2-OXOPYRROLIDIN-1-YL)BUTANAMIDE AND (S)-2-(2-e OXOPYRROLEDIN-1-YL)BUTANAMEDE IN A NON-RACEMIC RATIO

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8412357D0 (en) * 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
GB8827389D0 (en) 1988-11-23 1988-12-29 Ucb Sa Process for preparation of(s)alpha-ethyl-2-oxo-1-pyrrolidineacetamide

Also Published As

Publication number Publication date
DE69424009T2 (de) 2000-09-14
ZA947444B (en) 1995-05-11
HUT68299A (en) 1995-06-28
CA2132509A1 (en) 1995-03-25
HU217124B (hu) 1999-11-29
NO943521D0 (no) 1994-09-22
DE69424009D1 (de) 2000-05-25
NZ264506A (en) 1997-09-22
AU7416994A (en) 1995-04-06
GB9319732D0 (en) 1993-11-10
EP0645139A1 (fr) 1995-03-29
ES2145818T3 (es) 2000-07-16
ATE191849T1 (de) 2000-05-15
AU672334B2 (en) 1996-09-26
JP3688735B2 (ja) 2005-08-31
SG86284A1 (en) 2002-02-19
JPH07149639A (ja) 1995-06-13
US5447952A (en) 1995-09-05
EP0645139B1 (fr) 2000-04-19
TW283642B (fi) 1996-08-21
RU2142274C1 (ru) 1999-12-10
KR950007848A (ko) 1995-04-15

Similar Documents

Publication Publication Date Title
NO943521L (no) Anvendelse av et pyrrolidinacetamidderivat for fremstilling av et terapeutikum
ATE170510T1 (de) 3-(hydroxybenzylidenyl)-indolin-2-one und diese enthaltende arzneimittel
DE69201956D1 (de) Pyrrolidin- und thiazolidinderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
DK0613894T3 (da) N-Heteroaryl-N'-phenylurinstofderivater, fremstilling og anvendelse deraf
NO902800L (no) Fremgangsmaate for fremstilling av 11beta-aryl-4-oestrener.
ES2087625T3 (es) Derivados de ciclohexano sustituidos, procedimiento para su preparacion y el empleo de los compuestos para el tratamiento de enfermedades.
ES2103440T3 (es) Nuevas amidas y sulfonamidas naftalenicas, procedimiento de preparacion y composiciones farmaceuticas que las contienen.
MX9605458A (es) Derivados de amida y su uso terapeutico.
ES2123728T3 (es) Derivados de pirrolo-pirazina de actividad 5-ht3.
FI923662A (fi) Terapeutiska medel
DK0454429T3 (da) Anvendelse af 15-dehydroxy-16-oxoprostaglandinderivater til behandling af allergiske sygdomme
ES2095714T3 (es) Nuevas amino-alquil-cromonas, sus procedimientos de preparacion y las composiciones farmaceuticas que las contienen.
GR3003065T3 (en) Use of n-((1-ethyl-2-pyrrolidinyl)methyl)-methoxy-5-sulfamoyl benzamide in the treatment of sterility
ZA88639B (en) Substituted 3-phenyl-7h-thiazolo(3,2-b)(1,2,4)triazin-7-ones,a process for the preparation thereof,medicaments containing same and the use thereof,and also some intermediates formed in the preparation of the compounds mentioned
NO172339C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktiv (+)1-((3,4,5-trimetoksy)benzyloksymetyl)-1-fenyl-n,n-dimetyl-n-propylamin
NO172120C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive isoxazoler
DK0488044T3 (da) En imidazobenzodiazepin til behandling af søvnforstyrrelser
ZA917273B (en) Use of n-(1-hexahydroazepinylalkyl)acetamides in the preparation of medicaments for the treatment of cholinergic transmission disorders
GR3015592T3 (en) Pharmaceuticals containing substituted cyclohex-2-en-1-yl-amine derivatives and their use in combatting diseases.
NO156410C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive 6aaa-methylprednisolonderivater.
DK0671910T3 (da) Anvendelse af adamantanderivater til fremstilling af et lægemiddel til behandling af glaucoma
FR2742337B1 (fr) Application du 3-alpha-hydroxy-5-alpha-androsta-16-ene a titre de medicaments
IT1270689B (it) "derivati benzossazinonici e benzotiazinonici e loro uso terapeutico"
IT1245631B (it) Impiego di composti macrolidi come agenti anti-infiammatori per il trattamento di malattie provocate da cessione di istamina